Search Results

Following this tremendous experience, he was recruited to be the Principal Investigator of the Receptor To broaden his biomedical skill-set Stuart next accepted the position of Head of the Receptor Pharmacology Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based Stuart Maudsley on the web Maudsley Lab LinkedIn Google Scholar ResearchGate Maudsley Lab on Facebook Receptor

Following this tremendous experience, he was recruited to be the Principal Investigator of the Receptor To broaden his biomedical skill-set Stuart next accepted the position of Head of the Receptor Pharmacology Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based Stuart Maudsley on the web Maudsley Lab LinkedIn Google Scholar ResearchGate Maudsley Lab on Facebook Receptor

Samuel Hoare Sam completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors life science, and academic scientists in the development of new therapeutics and the understanding of receptor about his love for GPCRs, kinetics, and decorticate the complexities of GPCR function to better target receptors

Professor Pfleger has developed extensive expertise in profiling receptor binding and function at the globally-recognized expertise in bioluminescence resonance energy transfer (BRET) technology, including his patented Receptor-Heteromer Investigation Technology (Receptor-HIT) for studying heteromers.

GPCR Retreat Program < Back to schedule Structure-based discovery of functionally selective 5-HT1A receptor

pools with precision Tissue-level insights reshaping metabolic disease research What’s next: multiplex receptor labeling + AI-designed tools If GLP-1R biology, receptor trafficking, or advanced imaging are part of #GPCR #DrGPCR #metabolism #GLP1R #receptorbiology #fluorescenceimaging #drugdiscovery Previous Next Recent

Aaron is currently the Chief Scientific Officer and VP of Protein Engineering. Aaron has a proven track record as a biologics leader as he led teams to discover and develop novel first-in-class

His lab has worked on building large-scale ways of empirically exploring questions in protein biochemistry

This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor If your team relies on receptor visualization — discovery, screening, translational work — this story

Jens Carlsson challenges scientists to go beyond explaining data — and start predicting the future of receptor With tools like AlphaFold , his lab can now model receptor–peptide complexes in seconds — an achievement Yet Jens’s caution stands: prediction must be proven.

and worked closely with Dr Birgitte Holst studying structural and mechanistic properties of ghrelin receptor associated with obesity and other metabolic diseases, including GPR10, Melanocortin 4, Serotonin 2C and TRH receptors cell-based in vitro technologies to study mechanistic properties of GPCRs and understanding the dynamics of receptor Jacek shared his fascination with the growth hormone secretion receptor and the melanocortin 4 receptor Yamina, in turn, talked about her work on melanocortin receptors and an upcoming collaboration with a

Graciela Pineyro’s love for GPCR pharmacology started in Uruguay where she first worked on the serotonin receptors Graciela has done extensive work on the molecular pharmacology of opioid receptors, exploring their signaling

Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid receptors

Pluznick discovered that olfactory receptors in mice are also expressed in their kidneys and blood vessels GPCRs in regulating renal and cardiovascular function, and identifying renal/cardiovascular olfactory receptor

Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism Drug discovery often assumes receptor remains one of the few conceptual anchors that can tell us when “simple” truly is simple—and when deeper receptor Breakthroughs this week: Orphan receptor GPRC5B in neurogenesis; Septerna’s pill-based weight-loss strategy

sedative that prolongs exhalation and induces bradycardia—acting through alpha-2 adrenergic, not opioid, receptors investigates how fentanyl and xylazine shut down breathing through different mechanisms—work that blends receptor Listen now and see how one scientist is turning molecules into a mission, bridging the gap between receptor ecosystem , GPCR training program , GPCR podcast , opioid pharmacology , xylazine research , mu opioid receptor

pharmacology, and pharmacoepidemiology with innovative computational methods to gain novel insights into receptor identify human signaling systems and thereby discovered endogenous peptides activating several orphan receptors

Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism Drug discovery often assumes receptor remains one of the few conceptual anchors that can tell us when “simple” truly is simple—and when deeper receptor Breakthroughs this week: Orphan receptor GPRC5B in neurogenesis; Septerna’s pill-based weight-loss strategy

Ph.D. from Department of Pharmacology, University of Washington (1992, mentor Charley Chavkin , sigma receptors Focus on study of drugs and toxins on GPCR (opioid, cannabinoid receptor) and ion channel (K, Ca, TRP

Hannes Schihada Following studies in Pharmacy in Regensburg, Germany, I joined the receptor pharmacology I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors

episode Fiona Marshall got fascinated with GPCRs after attending a lecture on how the beta-adrenergic receptor biology, Fiona published the first description of the cloning and structural requirements of the GABAB receptor

focuses on the mechanisms underlying biased signaling at GPCRs, specifically, the role of differential receptor He primarily studies the chemokine receptor CXCR3 as it has three naturally occurring ligands and thus

developing a powerful new computational tool for identifying ‘surrogate’ ligands (borrowed from other receptors this expertise to establish a research program that takes orphan GPCRs from ‘locked’, inaccessible receptors

Since 2013, he has been elected Chair of the subcommittee for the Dopamine receptors of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification

San Francisco under the guidance of Professor Shaun Coughlin where she worked on the newly discovered protease-activated program is to gain a thorough and mechanistic understanding of processes that control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer progression. Her laboratory is the recognized expert on protease-activated receptors, particularly PAR1, and over

The result: a framework for designing ligands with altered receptor preferences. ♦️ Defines “public”

If you care about chemical biology, receptor visualization, or building tools that actually work in complex

years of experience in GPCR, primarily focused on drug discovery and developing new tools to study this receptor

identification of RAMPs (solving some CGRP family issues) and the GABA B, carboxylic, and nicotinic acid receptors

The focus of his research is the molecular pharmacology of cannabinoids and cannabinoid receptors.